3
Announcements
Trials
Browse
Landscape
Phase
Phase 1/2
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Dermatologic
1
Conditions
Skin Neoplasms
1
Neoplasms
1
Melanoma
1
Carcinoma, Merkel Cell
1
Carcinoma, Basal Cell
1
Carcinoma
1
Interventions
pembrolizumab
18
Nivolumab
13
avelumab
10
Ipilimumab
7
Specimen Handling
6
cemiplimab
5
atezolizumab
5
Magnetic Resonance Spectroscopy
5
Biopsy
5
Radiotherapy
3
Cyclophosphamide
3
prednylidene
2
poly ICLC
2
lutetium Lu 177 dotatate
2
fludarabine phosphate
2
fludarabine
2
durvalumab
2
deltacortene
2
aldesleukin
2
Radiosurgery
2
Prednisone
2
Interleukin-2
2
Immunoglobulin G
2
Docetaxel
2
CTLA-4 Antigen
2
Bevacizumab
2
tocilizumab
1
talimogene laherparepvec
1
sargramostim
1
relatlimab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoma, Merkel Cell
×
MAPRE1 protein, human
×
1 year
×
Clear all
NCT04349436
2026-04-22
ARTACUS
Replimune, Inc.
Phase 1/2
Active not recruiting
69 enrolled